Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 772-780

  Vergote, Ignace ^a   Finkler, Neil J ^b   Hall, James B ^c   Melnyk, Ostap ^d   Edwards, Robert P ^e   Jones, Marsha ^f   Keck, James G ^f   Meng, Lisa ^f   Brown, Gail L ^f   Rankin, Elaine M ^g   Burke, James J ^h   Boccia, Ralph V ⁱ   Runowicz, Carolyn D ^j   Rose, Peter G ^k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d Bay Area Cancer Research Group LLC   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f Telik Inc   (United States)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Center for Cancer and Blood Disorders   (United States)

^j UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Ovarian cancer; Phase 3 clinical trial; Platinum resistant

Indexed keywords

CANFOSFAMIDE; DOXORUBICIN; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEMATURIA; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; GLUTATHIONE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956807267     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181daaf59     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225Y249.
2. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: The state of the art. Int J Gynecol Cancer. 2005;15: 212Y220.
3. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1Y8.
4. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811Y2818.
5. Kauvar LM. Pharmaceutical targeting of GST isozymes. In: Tew KD, Pickett CB, Mantle TJ, Mannervice B, Hayes JD, eds. Structure and Function of Glutathione Transferases. Boca Raton, FL: CRC Press Inc; 1993: 257Y267.
6. Cowan KH, Batist G, Tulpule A, et al. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A. 1986;83:9328Y9332.
7. Teicher BA, Holden SA, Kelley MJ, et al. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987;47: 388Y393.
8. Lewis AD, Hayes JD, Wolf CR. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: Intrinsic differences and cell cycle effects. Carcinogenesis. 1988;9:1283Y1287.
9. Vergote I, Finkler N, del Campo J, et al. Phase 3 randomized study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer. Eur J Cancer. 2009;45:2324Y2332.
10. Montali JA, Wheatley JB, Schmidt DE Jr. Comparison of glutathione-S-transferase levels in predicting the efficacy of a novel alkylating agent. Cell Pharmacol. 1995;2:241Y247.
11. Doroshow JH. Anthracyclines and anthracenediones. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2001; 500Y537.
12. Kavanagh JJ, Garcia A, Choi H, et al. Efficacy of TLK286 (TELCYTA) Alone and With Paraplatin or Doxil (Caelyx) in Platinum-Resistant Ovarian CancerVResults From 3 Phase 2 Studies. Proceedings of the Biennial International Gynecologic Cancer Society Meeting; October 3Y7, 2004, Edinburgh, Scotland [Abstract no. 095].
13. Xu H, Namgoong S-Y, Roth E, et al. Synergistic Effect of TELCYTA (TLK286) in Combination With Paclitaxel, Doxorubicin, Carboplatin, Oxaliplatin, Cisplatin, Docetaxel, Gemcitabine and Iressa in Human Cancer Cells. Proceedings of the Annual Meeting of the American Association for Cancer Research; March 27-31, 2004, Orlando, FL [Abstract no. 2008].